Exelixis, Inc. (EXEL) Director George A. Scangos Sells 5,000 Shares

Share on StockTwits

Exelixis, Inc. (NASDAQ:EXEL) Director George A. Scangos sold 5,000 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the transaction, the director now owns 1,318,031 shares of the company’s stock, valued at approximately $32,950,775. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ EXEL opened at $24.53 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.50 and a quick ratio of 8.41. The firm has a market cap of $7.45 billion, a price-to-earnings ratio of 17.15, a PEG ratio of 0.77 and a beta of 2.22. Exelixis, Inc. has a twelve month low of $13.42 and a twelve month high of $25.19.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 12th. The biotechnology company reported $0.37 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.14. The business had revenue of $228.60 million during the quarter, compared to analyst estimates of $188.44 million. Exelixis had a return on equity of 48.90% and a net margin of 80.95%. Exelixis’s revenue was up 90.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.12 EPS. Research analysts expect that Exelixis, Inc. will post 1.04 earnings per share for the current fiscal year.

A number of equities analysts recently issued reports on the company. Zacks Investment Research cut Exelixis from a “buy” rating to a “hold” rating in a report on Monday, February 11th. BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a report on Saturday, March 9th. Cowen restated a “buy” rating and set a $29.00 price objective on shares of Exelixis in a report on Tuesday, February 26th. TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a report on Monday, December 17th. Finally, ValuEngine upgraded Exelixis from a “sell” rating to a “hold” rating in a report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $29.20.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BB&T Securities LLC raised its position in Exelixis by 3.6% during the 4th quarter. BB&T Securities LLC now owns 14,400 shares of the biotechnology company’s stock valued at $283,000 after purchasing an additional 500 shares in the last quarter. Cutler Capital Management LLC raised its position in Exelixis by 10.0% during the 4th quarter. Cutler Capital Management LLC now owns 11,000 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 1,000 shares in the last quarter. Chicago Equity Partners LLC raised its position in Exelixis by 2.0% during the 4th quarter. Chicago Equity Partners LLC now owns 52,360 shares of the biotechnology company’s stock valued at $1,030,000 after purchasing an additional 1,045 shares in the last quarter. FTB Advisors Inc. raised its position in Exelixis by 312.0% during the 4th quarter. FTB Advisors Inc. now owns 1,545 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,170 shares in the last quarter. Finally, JOYN Advisors Inc. raised its position in Exelixis by 334.2% during the 4th quarter. JOYN Advisors Inc. now owns 1,524 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 1,173 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Week Herald and is owned by of Week Herald. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://weekherald.com/2019/03/17/exelixis-inc-exel-director-george-a-scangos-sells-5000-shares.html.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Recommended Story: Marijuana Stocks Investing Considerations

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.